{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:08:50Z","timestamp":1780816130974,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To determine the prevalence and significance of anti-citrullinated vimentin and anti-citrullinated type II collagen antibodies and elucidate their role in the disease process of juvenile idiopathic arthritis (JIA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sera were obtained from 95 patients with various subtypes of JIA, 19 systemic lupus erythematosus (SLE) patients, and 10 healthy children. Antibodies were measured in the sera against citrullinated and native type II collagen and vimentin (vim1-16 and vim 59-74) by enzyme-linked immunosorbent assay. Samples were compared to anti-cyclic citrullinated peptide (anti-CCP) antibody and rheumatoid factor (RF) isotypes, and our previously measured anti-citrullinated fibrinogen and \u03b1-enolase antibodies on the same patient population, in addition to erythrocyte sedimentation rate and C-reactive protein. The relationship between the anti-citrullinated antibody profile and disease activity and joint damage were also investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-three JIA patients (24%) demonstrated reactivity to anti-citrullinated type II collagen. Ten JIA patients (10.5%) demonstrated reactivity to anti-citrullinated vimentin 1\u201316 antibodies and 7 (7.4%) to anti-citrullinated vimentin 59\u201374 antibodies. One IgM RF-positive polyarticular patient was positive for all 5 of the citrullinated autoantibodies tested. Thirty-seven different subsets of patients were identified based on their anti-citrullinated autoantibody and RF isotype profile. No significant associations were noted with anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies with joint damage or disease activity. Anti-citrullinated vimentin 59\u201374 antibodies demonstrated the highest overall specificity at 89.7%, with anti-citrullinated vimentin 1\u201316 and anti-citrullinated type II collagen antibodies at 86.2%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study demonstrates that antibodies to multiple citrullinated epitopes are present in the sera of patients with various subtypes of JIA. It also demonstrates the frequent occurrence of anti-citrullinated type II collagen and anti-citrullinated fibrinogen antibodies. The presence of autoantibodies to citrullinated antigens in JIA patients is highly diverse.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1546-0096-11-31","type":"journal-article","created":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T18:14:07Z","timestamp":1377800047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"11","author":[{"given":"Brooke E","family":"Gilliam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,29]]},"reference":[{"issue":"69","key":"996_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"2010","author":"D Aletha","year":"2010","unstructured":"Aletha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M\u00e9nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G: Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010, 2010 (69): 1580-1588.","journal-title":"Ann Rheum Dis"},{"key":"996_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004, 31: 390-392.","journal-title":"J Rheumatol"},{"key":"996_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1146\/annurev.immunol.26.021607.090244","volume":"26","author":"L Klareskog","year":"2008","unstructured":"Klareskog L, R\u00f6nnelid J, Lundberg K, Padyukov L, Alfredsson L: Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008, 26: 651-675. 10.1146\/annurev.immunol.26.021607.090244.","journal-title":"Annu Rev Immunol"},{"key":"996_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jbspin.2012.03.008","volume":"80","author":"A Omar","year":"2013","unstructured":"Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, Emad Y: Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine. 2013, 80: 38-43. 10.1016\/j.jbspin.2012.03.008.","journal-title":"Joint Bone Spine"},{"key":"996_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/08820130802438057","volume":"37","author":"HM Habib","year":"2008","unstructured":"Habib HM, Mosaad YM, Youssef HM: Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immuno Invest. 2008, 37: 849-857. 10.1080\/08820130802438057.","journal-title":"Immuno Invest"},{"key":"996_CR6","first-page":"492","volume":"26","author":"BE Gilliam","year":"2008","unstructured":"Gilliam BE, Chauhan AK, Low JM, Moore TL: Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol. 2008, 26: 492-497.","journal-title":"Clin Exp Rheumatol"},{"key":"996_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/ard.61.7.608","volume":"61","author":"T Av\u010din","year":"2002","unstructured":"Av\u010din T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V, Cecchini G, Borghi MO, Meroni PL: Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2002, 61: 608-611. 10.1136\/ard.61.7.608.","journal-title":"Ann Rheum Dis"},{"key":"996_CR8","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1136\/ard.2003.019331","volume":"63","author":"O Kasapcopur","year":"2004","unstructured":"Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-G\u00f6ksel A, Saribas S, Arisoy N, Kocazeybek B: Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2004, 63: 1687-1689. 10.1136\/ard.2003.019331.","journal-title":"Ann Rheum Dis"},{"key":"996_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1546-0096-9-8","volume":"9","author":"BE Gilliam","year":"2011","unstructured":"Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL: Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2011, 9: 8-10.1186\/1546-0096-9-8.","journal-title":"Pediatr Rheumatol Online J"},{"key":"996_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/ard.2007.084855","volume":"67","author":"RH Syed","year":"2008","unstructured":"Syed RH, Gilliam BE, Moore TL: Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2008, 67: 1049-1051.","journal-title":"Ann Rheum Dis"},{"key":"996_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/s10165-006-0498-y","volume":"16","author":"M Yoshida","year":"2006","unstructured":"Yoshida M, Tsuji M, Kurosaka D, Kurosaka D, Yasuda J, Ito Y, Nishizawa T, Yamada A: Autoimmunity to citrullinated type II collagen in rheumatoid arthritis. Mod Rheumatol. 2006, 16: 276-281. 10.1007\/s10165-006-0498-y.","journal-title":"Mod Rheumatol"},{"key":"996_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1084\/jem.20081862","volume":"206","author":"H Uysal","year":"2009","unstructured":"Uysal H, Bockerman R, Nandakumar KS, Sehnert B, Bajtner E, Engstr\u00f6m \u00c5, Serre G, Burkhardt H, Thunnissen MM, Holmdahl R: Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med. 2009, 206: 449-462. 10.1084\/jem.20081862.","journal-title":"J Exp Med"},{"key":"996_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/rheumatology\/keq419","volume":"50","author":"K Van Steendam","year":"2011","unstructured":"Van Steendam K, Tilleman K, Deforce D: The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology. 2011, 50: 830-837. 10.1093\/rheumatology\/keq419.","journal-title":"Rheumatology"},{"key":"996_CR14","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1515\/CCLM.2009.288","volume":"47","author":"AT Kuna","year":"2009","unstructured":"Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N: Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med. 2009, 47: 1525-1530.","journal-title":"Clin Chem Lab Med"},{"key":"996_CR15","first-page":"800","volume":"28","author":"H Morbach","year":"2010","unstructured":"Morbach H, Dannecker H, Karkau T, Girschick HJ: Prevalence of antibodies against mutated citrullinated vimentin and cyclic citrullinated peptide in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010, 28: 800-","journal-title":"Clin Exp Rheumatol"},{"key":"996_CR16","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/eji.200526000","volume":"35","author":"H Burkhardt","year":"2005","unstructured":"Burkhardt H, Sehnert B, Bockerman R, Engstr\u00f6m \u00c5, Kalden JR, Holmdahl R: Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol. 2005, 35: 1643-1652. 10.1002\/eji.200526000.","journal-title":"Eur J Immunol"},{"key":"996_CR17","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/art.23763","volume":"58","author":"A Ioan-Facsinay","year":"2008","unstructured":"Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, Elias B, M\u00e9nard HA, Newkirk M, Fritzler MJ, Toes RE, Huizinga TW, El-Gabalawy HS: Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008, 58: 3000-3008. 10.1002\/art.23763.","journal-title":"Arthritis Rheum"},{"key":"996_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.25036","volume":"62","author":"O Snir","year":"2010","unstructured":"Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, Lundberg K, Engstr\u00f6m A, Venables PJ, Toes RE, Holmdahl R, Klareskog L, Malmstr\u00f6m V: Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 2010, 62: 44-52. 10.1002\/art.25036.","journal-title":"Arthritis Rheum"},{"key":"996_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/ard.2004.029389","volume":"64","author":"MM Nielen","year":"2005","unstructured":"Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D: Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis. 2005, 64: 1199-1204. 10.1136\/ard.2004.029389.","journal-title":"Ann Rheum Dis"},{"key":"996_CR20","doi-asserted-by":"publisher","first-page":"R1421","DOI":"10.1186\/ar1845","volume":"7","author":"A Kinloch","year":"2005","unstructured":"Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D, Taylor PC, Venables PJ: Identification of citrullinated \u03b1-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R1421-R1429. 10.1186\/ar1845.","journal-title":"Arthritis Res Ther"},{"key":"996_CR21","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1002\/art.23936","volume":"58","author":"K Lundberg","year":"2008","unstructured":"Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, Mikuls TR, Venables PJ: Antibodies to citrullinated \u03b1-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum. 2008, 58: 3009-3019. 10.1002\/art.23936.","journal-title":"Arthritis Rheum"},{"key":"996_CR22","first-page":"1002","volume":"35","author":"L Innala","year":"2008","unstructured":"Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Rantap\u00e4\u00e4-Dahlqvist S: Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol. 2008, 35: 1002-1008.","journal-title":"J Rheumatol"},{"key":"996_CR23","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/art.24716","volume":"60","author":"MPM van der Linden","year":"2009","unstructured":"van der Linden MPM, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga WJ, Toes RE, van der Helm-van Mil AH: Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum. 2009, 60: 2232-2241. 10.1002\/art.24716.","journal-title":"Arthritis Rheum"},{"key":"996_CR24","first-page":"S56","volume":"23","author":"CB Lindsley","year":"1980","unstructured":"Lindsley CB, Janecek LL, Horton WA, Lindsley HB: IgG anticollagen antibodies in sera of patients with childhood rheumatic diseases [abstract]. Arthritis Rheum. 1980, 23: S56-","journal-title":"Arthritis Rheum"},{"key":"996_CR25","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V","volume":"44","author":"LK Myers","year":"2001","unstructured":"Myers LK, Higgins GC, Finkel TH, Reed AM, Thompson JW, Walton RC, Hendrickson J, Kerr NC, Pandya-Lipman RK, Shlopov BV, Stastny P, Postlethwaite AE, Kang AH: Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum. 2001, 44: 1775-1781. 10.1002\/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V.","journal-title":"Arthritis Rheum"},{"key":"996_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/art.1780390413","volume":"39","author":"ML Barnett","year":"1996","unstructured":"Barnett ML, Combitchi D, Trentham DE: A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 1996, 39: 623-628. 10.1002\/art.1780390413.","journal-title":"Arthritis Rheum"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1546-0096-11-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:10:26Z","timestamp":1630545026000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/1546-0096-11-31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,29]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1186\/1546-0096-11-31","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,29]]},"assertion":[{"value":"19 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"31"}}